摘要
欧盟在2000年即开始促进罕用药的使用,成员国陆续出台罕用药国家计划,建立了完善的罕用药医疗保障制度。其中,英国、比利时均设立了独立的药物评价机构和评审委员会,并引入多方利益相关者,基于疾病特点、药品需求和疗效、预算管理等标准,按多层次审评程序对罕用药的医保准入进行审查。这些做法对我国罕用药医保准入机制的完善具有借鉴意义。
The EU began to promote the use of orphan drug from 2000. Many member states have introduced national orphan drug program and established a comprehensive orphan drug health care system. Among them, the United Kingdom and Belgium have set up an independent drug evaluation mechanism and review committee, and introduced multi-stakeholder. The examination of access for Orphan Drug Medicare care according to the multi-level review process were done based on the characteristics of the disease, demand and efficacy of the drug, budget management and other standards. These practices have a reference to improve our access to orphan drug insurance mechanism.
关键词
罕用药
比利时
英国
医保报销
准入机制
Orphan drug
Belgium
Britain
medicare reimbursement
access mechanism
